ION224: A Promising Antisense Oligonucleotide Therapy for Metabolic Dysfunction-Associated Steatohepatitis (MASH)
The phase 2 ION224-CS2 trial demonstrates that ION224, a DGAT2 antisense oligonucleotide, safely improves liver histology in MASH patients independent of weight loss, offering a potential new therapeutic approach.